Avalo Therapeutics, Inc. - 8-K Filing
Avalo Therapeutics filed an 8-K on June 2, 2026 to report its annual stockholder meeting results. Stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan (ESPP), which was adopted by the board on April 2, 2026. The ESPP allows for up to 961,608 shares of common stock to be issued initially, with annual increases starting in 2027 based on company size or a fixed cap. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 below, at the Avalo Therapeutics, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $AVTX